▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Novo Nordisk (NYSE: NVO)

$66.96

(4.0%)

$2.58

Price as of May 19, 2025, 3:58 p.m. ET

Novo Nordisk Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
NVO	-48.14%	+124.27%	+17.53%	+55,899%
S&P	+12.45%	+100.69%	+14.95%	+4,512%

Novo Nordisk Company Info

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

News & Analysis

The Fool has written over 500 articles on Novo Nordisk.

Featured Article

Why Novo Nordisk Stock Just Slipped

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Rich Smith | May 16, 2025

Featured Article

Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months

Keith Speights | May 16, 2025

Why Weight-Loss Developer Stocks Tumbled on Tuesday

Eric Volkman | May 13, 2025

Why Novo Nordisk Stock Popped After Earnings

Rich Smith | May 7, 2025

Buying Novo Nordisk stock looks like the cheapest way to invest in GLP-1 drugs.

Novo Nordisk Predicts Strong Second Half

Matt Frankel | May 7, 2025

How to Invest in Eli Lilly (LLY)

Matt DiLallo | May 5, 2025

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

Rich Smith | May 2, 2025

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.

Is Novo Nordisk Stock a Buy?

Eric Volkman | May 2, 2025

Valuation

Podcast Episodes

Diabetes Deep-Dive: What Investors Need to Know About This Devastating Disease

Explaining diabetes, its various treatment options, and what the future may have in store for this disease.

Todd Campbell and Gaby Lapera | Jun 18, 2016

Earnings Transcripts

Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript

NVO earnings call for the period ending December 31, 2024.

Motley Fool Transcribing | Feb 5, 2025

Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript

NVO earnings call for the period ending September 30, 2024.

Motley Fool Transcribing | Nov 6, 2024

Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript

NVO earnings call for the period ending June 30, 2024.

Motley Fool Transcribing | Aug 7, 2024

Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript

NVO earnings call for the period ending March 31, 2024.

Motley Fool Transcribing | May 2, 2024

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services